Graphical model for estimating oral bioavailability of drugs in humans and other species from their caco-2 permeability and in vitro liver enzyme metabolic stability rates

被引:94
作者
Mandagere, AK
Thompson, TN
Hwang, KK
机构
[1] Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA
[2] Quintiles, Kansas City, MO 64134 USA
[3] Aventis Pharmaceut, Bridgewater, NJ 08807 USA
关键词
D O I
10.1021/jm010152k
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This paper describes a graphical model for simplifying in vitro absorption, metabolism, distribution, and elimination (ADME) data analysis through the estimation of oral bioavailability (%F) of drugs in humans and other species. This model integrates existing in vitro ADME data, such as Caco-2 permeability (P-app) and metabolic stability (percent remaining - %R) in liver S9 or microsomes, to estimate %F into groups of low, medium, or high regions. To test the predictive accuracy of our model, we examined 21 drugs and drug candidates with a wide range of oral bioavailability values, which represent approximately 10 different therapeutic areas in humans, rats, dogs, and guinea pigs. In vitro data from model compounds were used to define the boundaries of the low, medium, and high regions of the %F estimation plot. On the basis of the in vitro data, warfarin (93%), indomethacin (98%), timolol (50%), and carbamazepine (70%) were assigned to the high %F region; propranolol (26%) and metoprolol (38%) to medium %F region; and verapamil (22%) and mannitol (18%) to the low %F region. Similarly, the %F of 11 drug candidates from Elastase Inhibitor, NK1/NK2 antagonist, and anti-viral projects in rats, guinea pigs, and dogs were correctly estimated. This model estimates the oral bioavailability ranges of neutral, polar, esters, acidic, and basic drugs in all species. For a large number of drug candidates, this graphical model provides a tool to estimate human oral bioavailability from in vitro ADME data. When combined with the high throughput in vitro ADME screening process, it has the potential to significantly accelerate the processes of lead identification and optimization.
引用
收藏
页码:304 / 311
页数:8
相关论文
共 32 条
[1]  
ARTHURSSON P, 1991, BIOCH BIOPHYS COMMUN, V175, P880
[2]   Caco-2 monolayers in experimental and theoretical predictions of drug transport [J].
Artursson, P ;
Palm, K ;
Luthman, K .
ADVANCED DRUG DELIVERY REVIEWS, 1996, 22 (1-2) :67-84
[3]   Simultaneous pharmacokinetic screening of a mixture of compounds in the dog using API LC/MS/MS analysis for increased throughput [J].
Berman, J ;
Halm, K ;
Adkison, K ;
Shaffer, J .
JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (06) :827-829
[4]   Pharmacokinetic screening for the selection of new drug discovery candidates is greatly enhanced through the use of liquid chromatography atmospheric pressure ionization tandem mass spectrometry [J].
Bryant, MS ;
Korfmacher, WA ;
Wang, SY ;
Nardo, C ;
Nomeir, AA ;
Lin, CC .
JOURNAL OF CHROMATOGRAPHY A, 1997, 777 (01) :61-66
[5]  
BURHOLDER TP, 1997, BIOORG MED CHEM LETT, V7, P2531
[6]   Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats [J].
Chiou, WL ;
Barve, A .
PHARMACEUTICAL RESEARCH, 1998, 15 (11) :1792-1795
[7]  
Delie F, 1997, CRIT REV THER DRUG, V14, P221
[8]  
GARBER P, 1999, PHARM RES, V16
[9]  
GILMAN AG, 1990, PHARMACOL BASIS THER, P1655
[10]  
HO JC, 1999, HIGHER THROUGHPUT ME